303 related articles for article (PubMed ID: 32470166)
1. Optimal timing and treatment strategy for pancreatic cancer.
Gamboa AC; Rupji M; Switchenko JM; Lee RM; Turgeon MK; Meyer BI; Russell MC; Cardona K; Kooby DA; Maithel SK; Shah MM
J Surg Oncol; 2020 Sep; 122(3):457-468. PubMed ID: 32470166
[TBL] [Abstract][Full Text] [Related]
2. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
[TBL] [Abstract][Full Text] [Related]
3. The impact of neoadjuvant and adjuvant immunotherapy on the survival of pancreatic cancer patients: a retrospective analysis.
Amin S; Baine M; Meza J; Lin C
BMC Cancer; 2020 Jun; 20(1):538. PubMed ID: 32517661
[TBL] [Abstract][Full Text] [Related]
4. Is a Pathological Complete Response Following Neoadjuvant Chemoradiation Associated With Prolonged Survival in Patients With Pancreatic Cancer?
He J; Blair AB; Groot VP; Javed AA; Burkhart RA; Gemenetzis G; Hruban RH; Waters KM; Poling J; Zheng L; Laheru D; Herman JM; Makary MA; Weiss MJ; Cameron JL; Wolfgang CL
Ann Surg; 2018 Jul; 268(1):1-8. PubMed ID: 29334562
[TBL] [Abstract][Full Text] [Related]
5. Evaluating the Impact of ESPAC-1 on Shifting the Paradigm of Pancreatic Cancer Treatment.
Winer LK; Cortez AR; Ahmad SA; Wima K; Olowokure O; Latif T; Kharofa J; Patel SH
J Surg Res; 2021 Mar; 259():442-450. PubMed ID: 33059910
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant therapy offers longer survival than upfront surgery for poorly differentiated and higher stage pancreatic cancer.
Nurmi A; Mustonen H; Parviainen H; Peltola K; Haglund C; Seppänen H
Acta Oncol; 2018 Jun; 57(6):799-806. PubMed ID: 29241394
[TBL] [Abstract][Full Text] [Related]
7. Comparative Effectiveness of Neoadjuvant Chemoradiation Versus Upfront Surgery in the Management of Recto-Sigmoid Junction Cancer.
Venigalla S; Chowdhry AK; Wojcieszynski AP; Lukens JN; Plastaras JP; Metz JM; Ben-Josef E; Mahmoud NN; Reiss KA; Shabason JE
Clin Colorectal Cancer; 2018 Sep; 17(3):e557-e568. PubMed ID: 29910004
[TBL] [Abstract][Full Text] [Related]
8. Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation.
Estrella JS; Rashid A; Fleming JB; Katz MH; Lee JE; Wolf RA; Varadhachary GR; Pisters PW; Abdalla EK; Vauthey JN; Wang H; Gomez HF; Evans DB; Abbruzzese JL; Wang H
Cancer; 2012 Jan; 118(1):268-77. PubMed ID: 21735446
[TBL] [Abstract][Full Text] [Related]
9. Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial.
Jang JY; Han Y; Lee H; Kim SW; Kwon W; Lee KH; Oh DY; Chie EK; Lee JM; Heo JS; Park JO; Lim DH; Kim SH; Park SJ; Lee WJ; Koh YH; Park JS; Yoon DS; Lee IJ; Choi SH
Ann Surg; 2018 Aug; 268(2):215-222. PubMed ID: 29462005
[TBL] [Abstract][Full Text] [Related]
10. Defining the optimal timing of adjuvant therapy for resected pancreatic adenocarcinoma: A statewide cancer registry analysis.
Saeed H; Hnoosh D; Huang B; Durbin EB; McGrath PC; Desimone P; Maynard E; Anthony LB; Dineen SP; Hosein PJ; Tzeng CW
J Surg Oncol; 2016 Sep; 114(4):451-5. PubMed ID: 27238300
[TBL] [Abstract][Full Text] [Related]
11. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis.
Sugimoto M; Takahashi N; Farnell MB; Smyrk TC; Truty MJ; Nagorney DM; Smoot RL; Chari ST; Carter RE; Kendrick ML
J Surg Oncol; 2019 Nov; 120(6):976-984. PubMed ID: 31452208
[TBL] [Abstract][Full Text] [Related]
12. Predictive factors for long-term survival after surgery for pancreatic ductal adenocarcinoma: Making a case for standardized reporting of the resection margin using certified cancer center data.
Weyhe D; Obonyo D; Uslar VN; Stricker I; Tannapfel A
PLoS One; 2021; 16(3):e0248633. PubMed ID: 33735191
[TBL] [Abstract][Full Text] [Related]
13. Carbohydrate Antigen 19-9 Elevation in Anatomically Resectable, Early Stage Pancreatic Cancer Is Independently Associated with Decreased Overall Survival and an Indication for Neoadjuvant Therapy: A National Cancer Database Study.
Bergquist JR; Puig CA; Shubert CR; Groeschl RT; Habermann EB; Kendrick ML; Nagorney DM; Smoot RL; Farnell MB; Truty MJ
J Am Coll Surg; 2016 Jul; 223(1):52-65. PubMed ID: 27049786
[TBL] [Abstract][Full Text] [Related]
14. Vascular resection during pancreatectomy for pancreatic head cancer: A technical issue or a prognostic sign?
Belfiori G; Fiorentini G; Tamburrino D; Partelli S; Pagnanelli M; Gasparini G; Castoldi R; Balzano G; Rubini C; Zamboni G; Crippa S; Falconi M
Surgery; 2021 Feb; 169(2):403-410. PubMed ID: 32912782
[TBL] [Abstract][Full Text] [Related]
15. Nodal downstaging as a treatment goal for node-positive pancreatic cancer.
Portuondo JI; Massarweh NN; Zhang Q; Chai CY; Tran Cao HS
Surgery; 2019 Jun; 165(6):1144-1150. PubMed ID: 30745009
[TBL] [Abstract][Full Text] [Related]
16. Association of the location of pancreatic ductal adenocarcinoma (head, body, tail) with tumor stage, treatment, and survival: a population-based analysis.
van Erning FN; Mackay TM; van der Geest LGM; Groot Koerkamp B; van Laarhoven HWM; Bonsing BA; Wilmink JW; van Santvoort HC; de Vos-Geelen J; van Eijck CHJ; Busch OR; Lemmens VE; Besselink MG;
Acta Oncol; 2018 Dec; 57(12):1655-1662. PubMed ID: 30264642
[TBL] [Abstract][Full Text] [Related]
17. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
Michelakos T; Pergolini I; Castillo CF; Honselmann KC; Cai L; Deshpande V; Wo JY; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Nipp RD; Parikh A; Qadan M; Warshaw AL; Hong TS; Lillemoe KD; Ferrone CR
Ann Surg; 2019 Apr; 269(4):733-740. PubMed ID: 29227344
[TBL] [Abstract][Full Text] [Related]
18. Lymph Node Ratio in Pancreatic Adenocarcinoma After Preoperative Chemotherapy vs. Preoperative Chemoradiation and Its Utility in Decisions About Postoperative Chemotherapy.
Swords DS; Francis SR; Lloyd S; Garrido-Laguna I; Mulvihill SJ; Gruhl JD; Christensen MC; Stoddard GJ; Firpo MA; Scaife CL
J Gastrointest Surg; 2019 Jul; 23(7):1401-1413. PubMed ID: 30187332
[TBL] [Abstract][Full Text] [Related]
19. The significance of relative dose intensity in adjuvant chemotherapy of pancreatic ductal adenocarcinoma-including the analysis of clinicopathological factors influencing relative dose intensity.
Yabusaki N; Fujii T; Yamada S; Murotani K; Sugimoto H; Kanda M; Nakayama G; Koike M; Fujiwara M; Kodera Y
Medicine (Baltimore); 2016 Jul; 95(29):e4282. PubMed ID: 27442667
[TBL] [Abstract][Full Text] [Related]
20. The association of adjuvant therapy with survival at the population level following pancreatic adenocarcinoma resection.
Kagedan DJ; Raju RS; Dixon ME; Shin E; Li Q; Liu N; Elmi M; El-Sedfy A; Paszat L; Kiss A; Earle CC; Mittmann N; Coburn NG
HPB (Oxford); 2016 Apr; 18(4):339-47. PubMed ID: 27037203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
